H U : Notice of Conclusion of Agreement on Business Transfer by Consolidated Subsidiary of H.U. Group (Progress in Disclosure Item)
December 16, 2021 at 01:29 am
Share
December 15, 2021
For Immediate Release
Company name:
H.U. Group Holdings, Inc.
Representative:
Shigekazu Takeuchi, Director,
President and Group CEO
Securities code:
4544 First Section,
Tokyo Stock Exchange
Contact:
Atsuko Murakami,
Executive Officer and CFO
Telephone No.:
+81-3-5909-3337
Notice of Conclusion of Agreement on Business Transfer by Consolidated Subsidiary of H.U.
Group (Progress in Disclosure Item)
H.U. Group Holdings, Inc. (hereinafter the "Company") hereby announces that Fujirebio Inc. (President & CEO: Takeshi Fujita; Head Office: Shinjuku-ku, Tokyo; hereinafter "Fujirebio"), a consolidated subsidiary of the Company, concluded the Agreement on Business Transfer with Yamasa Corporation (President: Naoyuki Ishibashi; Head Office: Choshi-shi, Chiba; hereinafter "Yamasa") for transferring a part of the business of manufacturing and selling Fujirebio's radioimmunoassay (hereinafter "RIA"*) products to Yamasa as informed in an earlier release. Details are as follows.
1. Purpose of the business transfer
As disclosed in the Notice of Conclusion of Basic Agreement on Business Transfer by Consolidated Subsidiary of H.U. Group dated May 31, 2021, the Company defined "driving fixed-cost optimization through a focus on select manual product lines" as a key initiative in the IVD business under the medium-term plan, "H.U. 2025 ~Hiyaku (significant growth) & United~," announced in September 2020. To advance this initiative, the Company decided to transfer businesses related to certain RIA products, which are a major product line in the manual product category, including their manufacture and sale, to Yamasa.
Fujirebio and Yamasa recently concluded the Agreement on Business Transfer after agreeing to terms and conditions through discussions.
2. Outline of transferee and transferor Outline of transferor
(1)
Name
Fujirebio Inc.
(2)
Location
2-1-1 Nishishinjuku, Shinjuku-ku, Tokyo
(3)
Representative
Takeshi Fujita, President and CEO
(4)
Business
Manufacture, sale, export and import of clinical reagents and testing equipment
(5)
Capital
4.3 billion yen
Outline of transferee
(1)
Name
Yamasa Corporation
(2)
Location
2-10-1Araoi-cho,Choshi-shi, Chiba
(3)
Representative
Naoyuki Ishibashi, President
(4)
Business
Manufacture and sale of soy sauce, various seasonings and pharmaceuticals
(5)
Capital
100 million yen
3. Products subject to the transfer
Procollagen Intact PINP
Manufacturing and marketing authorization number: 22100AMY00001000
(2) Pyridinoline ICTP
Manufacturing and marketing authorization number: 20700AMY00152000
(3) 1,25 (OH) 2DRIA Kit 「FR」
Manufacturing and marketing authorization number: 20800AMY10137000
(4) Span-1・RIABEAD
Manufacturing and marketing authorization number: 20100AMZ00332000
4. Schedule
Business transfer
June 2023 (plan)
5. Outlook
The impact of the business transfer on our consolidated business results for the fiscal year ending March 31, 2022 is expected to be insignificant but we will promptly disclose any events arising in the future which require disclosure.
※ RIA (Radioimmunoassay): general term for immunoassay techniques using radioisotope labels
Attachments
Original Link
Original Document
Permalink
Disclaimer
Miraca Holdings Inc. published this content on 16 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 December 2021 06:28:11 UTC.
H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.